



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Rene Gantier et al.                      Art Unit : 1647  
Serial No. : 10/658,834                              Examiner : Stoica, Elly Gerald  
Filed : September 08, 2003                      Cust. No. : 7702  
Conf. No. : 7681  
Title : RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY,  
THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT**

Dear Sir:

Responsive the Office Action of December 26, 2007, consideration of the following amendments and remarks is requested.

**Amendment of the Sequence Listing** is provided on page 2 of this paper.

**Amendments** to the specification begin on page 3 of this paper.

**Amendments to the claims** are reflected in the listing of the claims, which begins on page 4 of this paper

**Remarks** begin on page 13 of this paper.

**An Appendix** is attached.


CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EM 247737451 US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service on the date indicated below and addressed to: Mail Stop Non Fee Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 26, 2008

Date of Deposit

Signature:

  
Kethya Teuk

Applicant : Rene Gantier *et al.*  
Serial No. : 10/658,834  
Filed : September 08, 2003

Attorney Docket No.: 0119365-00005/922  
Amendment and Response

## IN THE SEQUENCE LISTING

### **Please amend the Sequence Listing as follows:**

Replace the sequence listing in the above-captioned application with the attached replacement SEQUENCE LISTING. Two (2) CD-ROM copies and one (1) Computer Readable Format (CRF) of the SEQUENCE LISTING and a Verified Statement accompany this amendment. An annotated substitute sheet of SEQ ID NO:232 is included herein to point out the amendments made herein to the sequence listing. Applicants assert that the application is in compliance with 37 C.F.R. §§ 1.821-1.825 and that no new matter has been added.